Generation BioÂ Co (GBIO) Peer Comparison

$5.34

$-0.40 (-6.97%)

As on 10-Feb-2026 09:30EDT

Market cap

$36 Mln

Revenue (TTM)

$15 Mln

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Edit

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Market cap ($ Mln)	36	1,820	3,703
Revenue ($ Mln)	15	331	587
Net Profit ($ Mln)	-62.63	-43.40	-106.43
Net Margin (%)	-410.13	-13.13	-18.14
RoE (%)	-101.10	-8.15	--
Price to Earnings	--	--	--
Price-To-Book	0.71	3.30	5.29

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Operating Revenue	15.27	330.51	254.93
Cost of Revenue	1.40	55.62	6.53
Gross Profit	19.89	227.80	248.40
Operating Expenses	98.45	264.46	206.18
Operating Profit (EBIT)	-84.58	10.44	48.75
Other Income	0.00	0.00	--
Profit before Tax	-62.63	-40.61	53.94
Provision for Tax	0.00	2.79	--
Profit after Tax (Net Income)	-62.63	-43.40	48.83
Minority Interest	0.00	0.00	--
Consolidated Profit	0.00	0.00	--

Liabilities ($ Mln)

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Shareholder's Funds	50.56	534.14	-107.15
Minority Interest	0.00	0.00	--
Non-Current Liabilities	50.30	305.53	435.43
Current Liabilities	21.04	106.84	67.60
Total Liabilities	231.20	986.26	395.88

Assets ($ Mln)

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Non-Current Assets	28.43	132.18	221.08
Current Assets	93.46	814.33	174.81
Total Assets	231.20	986.26	395.88
Total Debt*	26.10	285.02	--
Net Current Assets	72.42	707.49	107.21

Cashflow ($ Mln)

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Cash From Operating Activities	-88.56	66.51	-10.91
Cash Flow from Investing Activities	94.53	-18.04	--
Cash from Financing Activities	0.25	-102.02	21.86
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
ROCE (%)	-54.77	3.16	-36.67
ROE (%)	-101.10	-8.15	-36.67
ROA (%)	-29.69	-3.97	14.46
EBIT Margin (%)	-414.88	-10.25	--
Net Margin (%)	-410.13	-13.13	19.16
Cash Profit Margin (%)	0.00	0.00	--

Growth Ratios

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Revenue Growth (%)	-17.82	26.73	0.60
EBIT Growth (%)	35.12	-207.38	--
Net Profit Growth (%)	56.95	-311.94	2,791.18
EPS Growth (%)	45.40	-420.34	--
Book Value Growth (%)	-52.03	-11.08	--

Valuation Ratios

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Price / Earnings	-0.05	71.55	--
Price / Book Value	0.08	3.27	--
Dividend Yield (%)	--	--	--
EV/EBITDA	1.14	32.71	--
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Debt to Equity	0.00	0.41	--
Short term debt to equity ratio	0.13	0.08	--
Current Ratio	4.44	7.62	2.59
Quick Ratio	4.44	6.94	--
Interest Coverage	--	-5.33	--

Operating Efficiency Ratios

	Generation BioÂ Co (GBIO)	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)
Debtors to sales (%)	2.56	22.18	17.80
Asset Turnover	0.07	0.30	0.75
Receivable days	52.39	60.23	45.21
Inventory Days	282.66	455.57	-182.56
Payable days	139.03	52.84	1,307.87
Cash Conversion Cycle	196.02	462.96	-649.00

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly